Despite its historical status as the “King” of cannabinoids, THC has seen significant competition from other cannabinoids, most notably CBD. Several factors have converged to create a rapidly developing market in non-THC cannabinoids such as CBG, CBC, THCV, delta-8 THC, and CBN. These factors include the removal of hemp-derived cannabinoids from the Controlled Substances Act, advancements in extraction technology, and an increasingly educated and engaged public. Using the current regulatory landscape of CBD as a jumping-off point, this panel will explore this new market from a regulatory standpoint. We will discuss what these cannabinoids are and how they are likely to be used; whether they will encounter similar regulatory obstacles as CBD in coming to market; and whether we should continue to think of cannabinoids as a unified “block” for regulatory purposes,or if they will each have separate paths.
This program is eligible for 1 hours of General CLE credit in 60-minute states, and 1.2 hours of General CLE credit in 50-minute states. Credit hours are estimated and are subject to each state’s approval and credit rounding rules.
INCBA webinars are eligible for credit in the following states: AR, AL, AK, AZ, CA, CO, CT,DE, GA, HI, IL, IN, MN, MS, MO, NV, NH, NJ, NM, NY, NC, ND, OH, OR, PA, TN, TX, UT, VT, WV, and WI . Additional states may be available for credit upon self-application by attendees. States typically decide whether a program qualifies for MCLE credit in their jurisdiction 4-8 weeks after the program application is submitted. For many live events, credit approval is not received prior to the program.
INCBA on demand programs are eligible for credit in the following states: AR, AL, AK, AZ, CA, CO, CT,DE, GA, HI, IL, IN, MN, MS, MO, NV, NH, NJ, NM, NY, NC, ND, OH, OR, PA, TN, TX, UT, VT, WV, and WI . Additional states may be available for credit upon self-application by attendees. States typically decide whether a program qualifies for MCLE credit in their jurisdiction 4-8 weeks after the program application is submitted.
For current accreditation status, please select your jurisdiction below.
| Abuhasira et al, 2018 (0.58 MB) | Available after Purchase | ||
| Which Will Be the Next CBD (0.69 MB) | Available after Purchase | ||
| Is CBN the Next Big Thing - A Legal Analysis (0.56 MB) | Available after Purchase | ||
| 2018 Farm Bill hemp provisions (0.05 MB) | Available after Purchase | ||
| Botanicals (0.20 MB) | Available after Purchase | ||
| ACS (1.54 MB) | Available after Purchase | ||
| Botanical Drug Development (0.21 MB) | Available after Purchase | ||
| Cannabinoids (0.67 MB) | Available after Purchase | ||
| CBD and the FDA - What Should the Hemp Industry Expect (0.68 MB) | Available after Purchase | ||
| Federal Analog Act (0.21 MB) | Available after Purchase | ||
| THC Analogs - A Family Divided (0.86 MB) | Available after Purchase | ||
| Schleider et al 2018 (0.20 MB) | Available after Purchase |
Rod is a cannabis business law attorney who lives in Asheville, NC. He represents legal
cannabis businesses throughout the country and is editor and chief writer of the Kight On
Cannabis law blog (www.kightoncannabis.com), a popular blog that discusses evolving legal
issues affecting the cannabis industry. Rod is the author of “Cannabis Business Law-What You
Need to Know”, published by Aspatore Books, a Thomson Reuters (WestLaw) Company, in
August 2015. Rod is on the advisory board for the American Journal of Endocannabinoid
Medicine (AJEM), for which he also writes a legal column. AJEM is the first printed, peer-
reviewed medical cannabis journal in North America. Rod is frequently interviewed on cannabis
matters by major media outlets and has been quoted in the Wall Street Journal, Time, Business
Insider, and Business Insurance.
A strong believer in cannabis for personal and medical use after using it successfully during
chemotherapy treatments for cancer (he is in remission), Rod is an attorney advocate for
NORML. He is also a member of the International Cannabis Bar Association, the National
Cannabis Industry Association, Women Grow, the Hemp Industries Association, and the North
Carolina Industrial Hemp Association. Rod has represented numerous cannabis businesses and
been a presenter on cannabis legal issues at seminars across the country. He has also drafted
and presented cannabis legislation to a foreign head of state.
Rod is married to his elementary school sweetheart, Ashley, who is also his office manager.
Together they have 5 children. Rod is an avid musician who plays guitar in an Asheville-based
rock band. He can be reached via email (rod@kightlaw.com) or phone (828-55-9881).
Dr. Hall is widely regarded as one of the most knowledgeable and outside the box thinkers in the cannabis industry. Having received his Bachelor of Science degree with a double major in Chemistry and Biology, Hall went on to pursue both his Masters and PhD at Florida Atlantic University, majoring in Chemistry with a focus on natural products chemistry.
Dr. Hall possesses a vast amount of experience in the laboratory space, holding senior positions in toxicology labs, clinical labs, and cannabis labs. He has been instrumental in leading labs through successful ISO 17025 accreditation in multiple states and most recently, at Green Scientific Labs in FL.
Daniel L. Young, PhD has worked at the forefront data sciences with a focus on healthcare innovation and systems biology for over seventeen years focusing on biomedical, machine learning, machine vision, pharmaceutical, diagnostic and healthcare applications. Dr. Young began his research career at the Harvard Biomotion Laboratory, Massachusetts General Hospital where he designed novel devices to aid in human motion and rehabilitation for patients. While a researcher and postdoctoral associate at Harvard-MIT Division of Health Sciences and Technology, Dr. Young investigated novel optimal control system strategies for biomedical applications inspired by his research of neural networks and synaptic plasticity. His research was applied to medical treatments and the control of complex nonlinear systems.
In his pursuit of advancing our fundamental understanding of complex, heterogeneous diseases, diagnostic approaches, and response to treatments, Dr. Young’s research utilizing advanced computational and machine learning algorithms has included the study of diabetes, respiratory disorders, neuroscience, oncology, infectious diseases, bone disorders, autoimmunity, renal disease, and anemia. Dr. Young and one of his colleagues were editors of a pioneering book on systems biology published in 2011 by Wiley, Inc., integrating the latest advancements in personalized medicine and systems approaches to the delivery of healthcare.
Dr. Young helped develop predictive biosimulations at Entelos, Inc. focused on quantitative models for the discovery and validation of drug targets, identification of biomarkers, proactive and personalized medicine, design of clinical trials, and ultimately advancing the effectiveness of preventative, therapeutic and monitoring solutions for patients. He founded Lemma Consulting focused on data-driven approaches to enhance novel technologies. And most recently, Dr. Young founded Grassland Botanicals to focus on natural plant-based luxury products for improving wellness.
Nathalie Bougenies’s practice focuses on the regulatory framework of hemp-derived CBD products. She is an authority on FDA enforcement, Food, Drug & Cosmetic Act and other laws and regulations surrounding hemp, hemp-derived cannabinoid products, including but not limited to CBD and CBG-infused products. Nathalie also advises clients on importing and exporting hemp, hemp products and products infused with hemp-derived cannabinoids to and from Europe and Latin America. Nathalie frequently speaks on these issues and has made national media appearances, including on NPR’s Marketplace.
Ian is founder and co-chair of the Cannabis and Hemp Law practice at Wilson Elser, an AmLaw 200 law firm with 900 attorneys in 39 offices in the United States and London. Ian leads a national multi-disciplinary team of lawyers who serve all aspects of the cannabis and hemp industries, as well as financial institutions and insurance companies that service those industries.
By way of background, Ian has defended complex litigation in state and federal courts for more than 20 years with a focus on practice areas relevant to the cannabis industry, including product liability, complex general casualty, transportation, data privacy and intellectual property litigation. Ian received his B.A. from Washington University in St. Louis, and his JD from Saint Louis University School of Law. He has been with Wilson Elser for the past 19 years.
Ian works with licensed cannabis operators throughout the country to comply with their obligations under the law and to develop risk management best practices. He advises Fortune 500 companies on risk management involving hemp-derived CBD and the interplay with U.S. food and drug laws. Ian assists insurance companies on cannabis-related underwriting practices and the development of new policy forms. He also works with financial institutions and professional services firms on best practices for operating in a challenging regulatory environment.
Ian participates on the Policy Council of the National Cannabis Industry Association (NCIA), is former chair of NCIA’s Finance and Insurance Committee, former vice-chair of the California Cannabis Industry Association (CCIA) Insurance Committee, and a member of the advisory board of the National Native American Cannabis Association. He is one of MG Magazine’s “30 Powerful Cannabis Attorneys You Should Know,” received a 2019 Readers’ Choice Award by JD Supra for his publication on cannabis consumer class actions, and received National Law Review’s award as “Go-To Thought Leader 2018” for his publications on cannabis law.
Please wait ...
